Neoepitope MHC Presentation Validation Using Recombinant Cell Display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to accurately predict which neoepitopes from tumor-specific mutations will be presented on the surface of cancer cells due to HLA gene complex diversity and intracellular processing uncertainties, limiting the efficacy of immune therapy.
Innovation Solution
A method involving recombinant expression systems, synthetic neoepitope peptides, and antibody-based assays to validate predicted MHC-presentation of neoepitopes, including steps such as transfecting cells with recombinant expression systems, generating synthetic antibodies, and detecting MHC presentation to confirm surface display.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neoepitopes are predicted based on tumor-specific mutations, then the specificity of immune therapy targets is improved, but the accuracy of predicting successful immune therapy targets deteriorates due to HLA gene complex diversity and intracellular processing uncertainties
Solution Approach 1:
The patent creates recombinant copies of predicted neoepitopes and displays them on the surface of cells (such as RAG-deficient T cells or other suitable cells). This allows direct observation and validation of which predicted neoepitopes are actually presented by MHC molecules, thereby resolving the uncertainty in prediction accuracy while maintaining the specificity gained from tumor mutation analysis
Solution Approach 2:
The patent introduces an intermediary validation step using recombinant expression systems and antibody-based assays. The recombinant neoepitopes serve as intermediaries between the predicted tumor mutations and the actual immune response assessment, allowing researchers to verify MHC presentation before proceeding to full immune therapy development
2Adaptability or versatility
If comprehensive neoepitope screening is performed to identify all potential targets, then the coverage of immune therapy targets is improved, but the complexity of the validation process increases due to the need to test numerous candidates
Solution Approach 1:
The patent segments the validation process into distinct modular steps: (1) identification of tumor-specific mutations, (2) prediction of neoepitopes, (3) construction of recombinant expression systems for individual neoepitopes, (4) validation using antibody-based assays, and (5) selection of successful targets. This segmentation allows comprehensive screening of multiple candidates while managing complexity through systematic organization of the validation workflow
Solution Approach 2:
The patent changes the physical state and presentation parameters of neoepitopes by expressing them as recombinant proteins on cell surfaces. This standardization of presentation format allows high-throughput screening of multiple neoepitope candidates using consistent assay conditions, thereby increasing coverage while controlling validation complexity
Data Source
AI summary
Systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor are disclosed. The methods use sequence information of the neoepitope.